Korean J Pediatr.
2009 Jan;52(1):93-98. 10.3345/kjp.2009.52.1.93.
Outcome of patients with neuroblastoma aged less than 1 year at diagnosis
- Affiliations
-
- 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kwsped@skku.edu
- 2Department of Pediatric Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 3Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 4Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- KMID: 2037343
- DOI: http://doi.org/10.3345/kjp.2009.52.1.93
Abstract
- PURPOSE
The purpose of this study was to evaluate the clinical characteristics and outcomes of patie nts with neuroblastoma aged less than 1 year.
METHODS
From January 1997 to December 2007, 41 patients aged less than 1 year were diagnosed with neuroblastoma. Patients were divided into 3 risk groups according to the stage of the disease and N-myc amplification. Low-risk patients underwent surgery with (stage 2) or without (stage 1) short-term chemotherapy. Intermediate-risk patients underwent chemotherapy and surgery with or without local radiation therapy. High-risk patients underwent chemotherapy, surgery, radiation therapy, and high-dose chemotherapy/autologous stem cell rescue (HDCT/ASCR).
RESULTS
While tumor relapse occurred in only 1 patient, 7 patients died of treatment-related toxicities. Causes of treatment-related death included infection during conventional chemotherapy in 5 patients and acute myocarditis during HDCT/ASCR in 2 patients. The overall 5-year survival (+/-standard error) and 5-year event-free survival (EFS) rates after diagnosis for all 41 patients were 82.8+/-5.9% and 80.0+/-6.3%, respectively, with a median follow-up of 58 (9-137) months. The 5-year EFS rates for low-risk, interme diate-risk, and high-risk patients were 100%, 68.4+/-10.8%, and 66.7+/-19.3%, respectively.
CONCLUSION
Increased efforts to reduce infection-associated toxicity deaths during conventional chemotherapy are needed to further improve the survival of patients with neuroblastoma aged less than 1 year.
